AI Native Biopharma Advancing Global and Misutilized AssetsAI NativeBiopharmaAdvancing GlobalandMisutilized Assets
A Quantitative AI Engine that Systematizes the Search, Evaluation, and Development of Pharma assets.
We work where biology
is hardest, and bring back
candidates that translate.
Approach
A self-optimizing research initiative in the optimization of pharma supply, distribution, and value creation. From ecology, to marine biology, to in-silico testing and policy and economic changes, an AI agent pharma ontology built for seeing opportunities throughout the noise.
Two operational layers, one platform.
Computational biology
Foundation models trained on 1.2B annotated biological sequences predict protein–compound interactions in silico, surfacing leads weeks ahead of physical assay. The graph is updated nightly with every new wet-lab readout.
Translational clinical
A biomarker-led clinical team carries promising candidates through IND-enabling studies and Phase 1 in partnership with academic medical centers across three continents.
By the numbers.
Real-world data points continuously tracked across the platform.
Faster deal search, evaluation, and execution end-to-end.
More qualified opportunities identified vs. legacy workflows.
Become a partner.
We partner with pharma, foundation, and venture-backed programs on co-developed discovery and translational work. New engagements typically begin with a two-week feasibility sprint.